Related Experiment Video
Updated: Jan 20, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
Is ulcerative colitis a disease of a dysfunctional microbiota?
1Infectious Diseases Incorporated, 17121 Lakewood Drive, Bellevue, NE 68123-3954, United States.
This study challenges current ulcerative colitis understanding, highlighting the gastrointestinal microbiota's role in disease and recovery. Fecal enema therapy shows superior remission rates compared to biologics.
Area of Science:
- Gastroenterology
- Microbiology
- Immunology
Background:
- Current understanding of ulcerative colitis (UC) is questioned.
- Crohn's disease has been decoupled from inflammatory bowel disease (IBD).
Purpose of the Study:
- To re-evaluate the definition and therapeutic strategies for ulcerative colitis.
- To investigate the role of the gastrointestinal microbiota in UC.
Main Methods:
- Review of gross pathology literature.
- Analysis of fecal enema therapy remission rates.
- Comparison with biologic therapy remission rates.
Main Results:
- Fecal enema therapy demonstrates significantly superior remission rates compared to biologics for UC.
- The gastrointestinal microbiota appears dominant in UC induction and recovery.
- The concept of endogenous enterotoxogenesis is proposed.
Conclusions:
- Ulcerative colitis may require a revised understanding of its pathogenesis.
- Targeting the gastrointestinal microbiota presents a promising therapeutic avenue for UC.
- Endogenous enterotoxogenesis offers a new perspective on UC development.
More Related Videos
Related Concept Videos
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Ulcerative Colitis in IBD
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...

